229 related articles for article (PubMed ID: 23133884)
1. [Tapentadol prolonged release for severe chronic pain. Results of a non-interventional study involving general practitioners and internists].
Schwittay A; Schumann C; Litzenburger BC; Schwenke K
MMW Fortschr Med; 2012 Oct; 154 Suppl 3():85-93. PubMed ID: 23133884
[TBL] [Abstract][Full Text] [Related]
2. [Tapentadol prolonged release for the treatment of severe chronic tumor pain in routine clinical practice].
Agbalaka A; Schwenke K; Litzenburger B
MMW Fortschr Med; 2012 Dec; 154 Suppl 4():123-30. PubMed ID: 23326931
[TBL] [Abstract][Full Text] [Related]
3. [Tapentadol prolonged release improves analgesia, functional impairment and quality of life in patients with chronic pain who have previously received oxycodone/naloxone].
Kern KU; Krings D; Waldmann-Rex S
MMW Fortschr Med; 2014 Jul; 156 Suppl 2():54-63. PubMed ID: 25351028
[TBL] [Abstract][Full Text] [Related]
4. Tapentadol prolonged release for severe chronic pain: results of a noninterventional study involving general practitioners and internists.
Schwittay A; Schumann C; Litzenburger BC; Schwenke K
J Pain Palliat Care Pharmacother; 2013 Aug; 27(3):225-34. PubMed ID: 23957433
[TBL] [Abstract][Full Text] [Related]
5. [Clinical practice data regarding tapentadol prolonged release treatment for severe chronic pain - improvement of analgesia, functional competence and quality of life in particular under tapentadol monotherapy].
Lange T; Krings D; Waldmann-Rex S
MMW Fortschr Med; 2015 Apr; 157(157 Suppl 4):12-21. PubMed ID: 26013114
[TBL] [Abstract][Full Text] [Related]
6. [Conversion to tapentadol PR improves analgesia and quality of life in patients with severe and chronic pain despite using tramadol > 300 mg/d].
Richter U; Waldmann-Rex S; Lehmann U
Wien Klin Wochenschr; 2015 Jun; 127(11-12):477-87. PubMed ID: 25409951
[TBL] [Abstract][Full Text] [Related]
7. Management of severe chronic pain with tapentadol prolonged release - long-term data from pain specialists.
Strick V
Curr Med Res Opin; 2014 Oct; 30(10):2085-92. PubMed ID: 24983745
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and tolerability of tapentadol prolonged release compared with prior opioid therapy for the management of severe, chronic osteoarthritis pain.
Steigerwald I; Schenk M; Lahne U; Gebuhr P; Falke D; Hoggart B
Clin Drug Investig; 2013 Sep; 33(9):607-19. PubMed ID: 23912473
[TBL] [Abstract][Full Text] [Related]
9. Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase 3b study.
Gálvez R; Schäfer M; Hans G; Falke D; Steigerwald I
Adv Ther; 2013 Mar; 30(3):229-59. PubMed ID: 23475406
[TBL] [Abstract][Full Text] [Related]
10. Tapentadol Prolonged Release for Severe Chronic Osteoarthritis Pain in the Elderly-A Subgroup Analysis of Routine Clinical Practice Data.
Schwittay A; Sohns M; Heckes B; Elling C
Pain Res Manag; 2020; 2020():5759265. PubMed ID: 32351639
[TBL] [Abstract][Full Text] [Related]
11. [Tapentadol prolonged release for severe chronic pain. Results of a non-interventional study involving general practitioners and internists].
Schwittay A
MMW Fortschr Med; 2013 Jan; 155(1):64. PubMed ID: 23573727
[No Abstract] [Full Text] [Related]
12. Practical considerations for the use of tapentadol prolonged release for the management of severe chronic pain.
Sánchez Del Águila MJ; Schenk M; Kern KU; Drost T; Steigerwald I
Clin Ther; 2015 Jan; 37(1):94-113. PubMed ID: 25108647
[TBL] [Abstract][Full Text] [Related]
13. Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain.
Kress HG; Koch ED; Kosturski H; Steup A; Karcher K; Lange B; Dogan C; Etropolski MS; Eerdekens M
Pain Physician; 2014; 17(4):329-43. PubMed ID: 25054392
[TBL] [Abstract][Full Text] [Related]
14. Direct conversion from tramadol to tapentadol prolonged release for moderate to severe, chronic malignant tumour-related pain.
Kress HG; Koch ED; Kosturski H; Steup A; Karcher K; Dogan C; Etropolski M; Eerdekens M
Eur J Pain; 2016 Oct; 20(9):1513-8. PubMed ID: 27062079
[TBL] [Abstract][Full Text] [Related]
15. Tapentadol Prolonged Release for Chronic Pain: A Review of Clinical Trials and 5 Years of Routine Clinical Practice Data.
Baron R; Eberhart L; Kern KU; Regner S; Rolke R; Simanski C; Tölle T
Pain Pract; 2017 Jun; 17(5):678-700. PubMed ID: 27611642
[TBL] [Abstract][Full Text] [Related]
16. Tapentadol prolonged release in patients with chronic low back pain: real-world data from the German Pain eRegistry.
Überall MA; Elling C; Eibl C; Müller-Schwefe GH; Lefeber C; Heine M; Heckes B
Pain Manag; 2022 Mar; 12(2):211-227. PubMed ID: 34376059
[TBL] [Abstract][Full Text] [Related]
17. [Tapentadol versus classical WHO-III opioids for chronic back pain. Health services research study based on representative data from health insurance funds].
Kern KU; Vogelmann T; Tölle TR
MMW Fortschr Med; 2022 Apr; 164(Suppl 6):19-27. PubMed ID: 35449488
[TBL] [Abstract][Full Text] [Related]
18. Ready conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended release.
Imanaka K; Tominaga Y; Etropolski M; Ohashi H; Hirose K; Matsumura T
Clin Drug Investig; 2014 Jul; 34(7):501-11. PubMed ID: 24906437
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR for the Management of Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-Label, Phase 3b/4 Study.
Baron R; Likar R; Martin-Mola E; Blanco FJ; Kennes L; Müller M; Falke D; Steigerwald I
Pain Pract; 2016 Jun; 16(5):580-99. PubMed ID: 26095455
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of tapentadol prolonged release for pre- and post-operative low back pain: a prospective observational study.
Bagaphou TC; Cerotto V; Gori F
Eur Rev Med Pharmacol Sci; 2019 Nov; 23(4 Suppl):14-20. PubMed ID: 31755078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
